We are a biopharmaceutical company focused on developing innovative products for the prevention and treatment of serious and potentially life-threatening infectious diseases.
We are currently focused on developing oral, small molecule compounds to prevent and treat a number of viral respiratory infections. Our most advanced clinical-stage program is laninamivir octanoate (LANI), a long-acting neuraminidase inhibitor we are developing under an Investigation New Drug Application (IND) for the treatment of influenza A and B infections. We have recently completed enrollment in IGLOO, a global 640 patient Phase 2 trial. Top-line data from the IGLOO trial are anticipated to be available in Q3, 2014. LANI has been successfully developed and approved for the treatment and prophylaxis of influenza A & B in Japan by Daiichi Sankyo.
Vapendavir (BTA798) is a second compound we have advanced into Phase 2 clinical development for the treatment of human rhinovirus ("HRV") infections in moderate to severe asthmatic and patients with COPD. We also have a preclinical program focused on developing BTA-C585, an orally bioavailable fusion inhibitor for the treatment of respiratory syncytial virus (RSV) infections in children, the elderly and immunocompromised patients.
In addition to our research and development activities, we receive royalty revenue from two approved neuraminidase inhibitors: zanamivir, marketed worldwide as Relenza® by GlaxoSmithKline; and LANI, marketed in Japan as Inavir® by Daiichi-Sankyo.